Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2008

01-09-2008 | Case Reports

Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab

Authors: Alicia Lázaro, Javier Cassinello, Almudena Amorós, Miriam Heredia, Ana López-Alfonso

Published in: Clinical and Translational Oncology | Issue 9/2008

Login to get access
Metadata
Title
Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab
Authors
Alicia Lázaro
Javier Cassinello
Almudena Amorós
Miriam Heredia
Ana López-Alfonso
Publication date
01-09-2008
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 9/2008
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-008-0255-6

Other articles of this Issue 9/2008

Clinical and Translational Oncology 9/2008 Go to the issue

Editorial

Retinoblastoma. Can we do more?

Educational Series

Molecular biology of pancreatic cancer

Correspondence

An autopsy case of acute pulmonary toxicity related to irinotecan

Special Article

Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007

Research Articles

Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review

Brief Research Articles

Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits